Personal profile

Research interests

Research Expertise:  Very wide experience of synthetic organic, biological and medicinal chemistry, much of it focused in collaborations with academic life science groups and pharmaceutical industry to unravel aspects of key cellular signalling pathways and develop compounds to modulate these with a therapeutic outcome. Major projects since 2000 have included: design and synthesis of phosphodiesterase type 4 (PDE4) inhibitors, protein tyrosine phosphatase 1B (PTP1B) inhibitors and chemokine receptor (CXCR2) antagonists for treatment of asthma, diabetes and chronic obstructive pulmonary disease respectively (UK£2m industrial funding, as part of programmes of total value >UK£15m); design and synthesis of compounds to modulate stem cell development (£1m from ITI Life Sciences as part of programme of total value UK£9.5m). co-I on recently commenced multicentre programme funded by the Scottish Funding Council (2011, UK£2.5m) to develop protocols for red blood cell production from pluripotent stem cells. co-I on additional awards from UK Research Councils and NHS totaling UK£0.94m since 2000 for research on nitric oxide synthase and on programmes directed towards the discovery of natural products with antimicrobial activity against organisms responsible for nosocomial infections. Additional interests in the function of RACK1 as a scaffolding protein, GPCR signalling (free fatty acid receptor 2), RTK signalling (IGF1R), the design and synthesis of functional nitric oxide synthase mimetics and in antiviral medicinal chemistry. Experienced collaborator with academic life science groups working on cellular signalling pathways [Houslay group, Glasgow Univ, exploration of PDE4 structure and function; contributing to MRC/G0400053 (1/10/2006, 48 months, UK£1.9m) & EU FP6/037189 (1/10/2006, 36 months, €3m)] [Milligan group, Glasgow Univ, ligands for FFA2; contributing to Wellcome Trust 089600/Z/09/Z (2010, 36 months, UK£231k)]. A major current focus is on the role of RACK1 in IGF-I/adhesion-mediated signalling relevant to regulation of cytoskeleton and cell motility (analysis of interactions with partner proteins – actin, myosin, PKC, FAK etc) collaborations with (O’Connor gp, Cork;  Kiely group, Limerick;  Long gp, Trinity College Dublin;  Ron gp, UCSF).

Research interests

biological chemistry

medicinal chemistry

GPCR signalling

RTK signalling

cyclic nucleotide signalling


RACK1 scaffolding protein



nitric oxide synthase

antiviral medicinal chemistry


natural products


  • QD Chemistry

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Phosphoric Diester Hydrolases Medicine & Life Sciences
Phosphodiesterase Inhibitors Medicine & Life Sciences
peptide Earth & Environmental Sciences
Type 4 Cyclic Nucleotide Phosphodiesterase Medicine & Life Sciences
inhibitor Earth & Environmental Sciences
inhibitors Physics & Astronomy
protein Earth & Environmental Sciences
Arrestin Medicine & Life Sciences

Co Author Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2017

FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system

Yalla, K. C., Elliott, C., Day, J. P., Findlay, J., Barratt, S., Hughes, Z. A., Wilson, L., Whiteley, E., Popiolek, M., Li, Y., Dunlop, J., Killick, R., Adams, D. R., Brandon, N. J., Houslay, M. D., Hao, B. & Baillie, G. S. 20 Jul 2017 In : Molecular Psychiatry. p. 1-9 9 p.

Research output: Contribution to journalArticle

Open Access

Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners

Houslay, K. F., Christian, F., MacLeod, R., Adams, D. R., Houslay, M. D. & Baillie, G. S. 3 Feb 2017 In : Biochemical Journal. 474, 4, p. 597-609 13 p.

Research output: Contribution to journalArticle

Open Access
Type 4 Cyclic Nucleotide Phosphodiesterase
Sexual Partners
Catalytic Domain
Cyclic AMP
Protein Kinases

Identification of a Novel, Small Molecule Partial Agonist for the Cyclic AMP Sensor, EPAC1

Parnell, E., McElroy, S. P., Wiejak, J., Baillie, G. L., Porter, A., Adams, D. R., Rehmann, H., Smith, B. O. & Yarwood, S. J. 22 Mar 2017 In : Scientific Reports. 7, 294

Research output: Contribution to journalArticle

Open Access

Sphingosine 1-phosphate and cancer

Pyne, N. J., El Buri, A., Adams, D. R. & Pyne, S. 15 Sep 2017 In : Advances in Biological Regulation.

Research output: Contribution to journalArticle

Lysosphingolipid Receptors

Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors

Pyne, N. J., Adams, D. R. & Pyne, S. Jul 2017 In : Trends in Pharmacological Sciences. 38, 7, p. 581-591

Research output: Contribution to journalArticle

Autoimmune Diseases
Histone Deacetylase 2
Histone Deacetylase 1